Odyssey Therapeutics, Inc. ODTX
19.14 USD -0.96 (-4.78%)
At closeNov 13, 2026, 4:26 PM EST
19.14 0.00 0.00%
After hours · Nov 13, 4:26 PM ET
18.46 Day range 19.76
15.56 52-week range 28.76
- YTD
- +16.57%
- 1 year
- +16.57%
News
benzinga.com Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
globenewswire.com Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism “Cutting Edge” article demonstrates that compared with IL-2, TNFR2 agonism promotes tissue-directed regulatory T-cell differentiation and lineage stability, as well as reduces autoimmune inflammation…
benzinga.com HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40 HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.
benzinga.com Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.08) by 1.85 percent.
benzinga.com UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27 UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.
benzinga.com Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and- benzinga.com Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42 Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $42.
benzinga.com This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
benzinga.com HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44 HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.
benzinga.com JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29 JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.
benzinga.com Odyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of…- benzinga.com Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.
- benzinga.com Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(6.77) per share which missed the analyst consensus estimate of $(1.13) by 499.12 percent. This is a 82.8 percent increase over losses…
- benzinga.com Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight Rating Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating.
- benzinga.com Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30 Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.
benzinga.com JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26 JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating and announces Price Target of $26.
benzinga.com This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for all changes. MOBI target prices: $16, $19, $31
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Doximity, Aeluma, PDF Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures rise on Dow gaining 200 points. Doximity (DOCS) shares drop 21.3% after reporting mixed Q4 results and weak guidance. Other stocks also decline in pre-market trading.